SMAD family member 7Genealiases: CRCS3 · MADH7 · MADH8
Q-omics provides the consensus-scored SMAD7 profile across patient tissues and cancer cell-line models. SMAD7 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SMAD7 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, SMAD7 RNA expression shows 20,047 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUSC, COAD, and ACC as cancer lineages where SMAD7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMAD7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMAD7 survival associations across molecular data types. SMAD7 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMAD7 RNA expression–survival associations across cancer types. High SMAD7 expression shows unfavorable associations in LUSC and ACC, but favorable associations in LGG, KIRC, LUAD and SKCM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SMAD7 RNA expression.
This table summarizes SMAD7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SMAD7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMAD7 shows lower tumor expression in COAD, LUAD, LUSC, KICH and THCA and higher tumor expression in HNSC. The COAD box plot shows higher SMAD7 RNA expression in normal versus tumor tissue (log2 FC = −1.255, t-test p < 0.001).
This table shows molecular features associated with SMAD7 in patient tissues and cancer cell lines. In patient samples, SMAD7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, SMAD7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and KIDNEY.
